Shukra Pharmaceuticals Limited has been authorised by Wockhardt Limited, a leading global pharmaceutical company, on a PAN India basis to represent, distribute, and manage its products across:  all ESIC/ESIS hospitals across India and all Defence Hospitals / AFMSD / DGAFMS units across India.

The company is in receipt of this non-exclusive authorization on September 9, 2025, valid till March 2026, empowers Shukra Pharmaceuticals Limited to quote products on behalf of Wockhardt Limited, collect order copies and raise invoices, collect payments directly on behalf of Wockhardt Limited.

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin), which are breakthrough antibiotics developed to combat critical infections.

This strategic distributorship from Wockhardt Limited, a respected name in global healthcare, marks a significant milestone in the growth journey of Shukra Pharmaceuticals Limited.

The arrangement will strengthen the Company's presence in institutional and government healthcare networks across India, enhance revenue visibility and operational footprint, create long-term value for shareholders by aligning with India's expanding healthcare and hospital infrastructure.